Is the Office of Scientific Integrity Too Zealous?

Since administrators naturally wish to protect their institutions from embarrassment, it is not surprising that they have often been reluctant to respond to allegations of fraud in research. We are now paying the price for this reticence, as congressional investigations have exposed a substantial number of fraud cases--more than most scientists would have expected. Nevertheless, the recognition of even one or two dozen cases of fraud among the 24,000 grants supported by the National Institutes

Written byJulia King
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Some legislators, however, perceive a more serious crisis, and in response to their criticism, the Department of Health and Human Services established two offices: its own Office of Scientific Integrity Review and the Office of Scientific Integrity (OSI) in NIH.

While it was necessary to strengthen the NIH mechanisms for dealing with fraud, the existence of two offices, for a function that could well be performed by one, wastes both money and time. More disturbing than their structure is the broad mandate of these new offices, which instructs them not only to monitor and conduct investigations of misconduct but also to "promote high standards of laboratory and clinical investigations in science through a prevention and education program."

This phrasing is fraught with possibilities for encouraging the government to mix problems of misconduct with problems of quality in the conduct of research. And even though the government may wish to be ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies